IL84275A - Pharmaceutical composition comprising erythropoietin for treatment of iron overload disorders - Google Patents

Pharmaceutical composition comprising erythropoietin for treatment of iron overload disorders

Info

Publication number
IL84275A
IL84275A IL84275A IL8427587A IL84275A IL 84275 A IL84275 A IL 84275A IL 84275 A IL84275 A IL 84275A IL 8427587 A IL8427587 A IL 8427587A IL 84275 A IL84275 A IL 84275A
Authority
IL
Israel
Prior art keywords
erythropoietin
treatment
pharmaceutical composition
iron overload
iron
Prior art date
Application number
IL84275A
Other languages
English (en)
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of IL84275A publication Critical patent/IL84275A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Oxidation Or Reduction (AREA)
  • Manufacture Of Iron (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogen, Water And Hydrids (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Iron (AREA)
IL84275A 1986-11-21 1987-10-25 Pharmaceutical composition comprising erythropoietin for treatment of iron overload disorders IL84275A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/933,495 US5013718A (en) 1986-11-21 1986-11-21 Method for treating iron overload using EPO

Publications (1)

Publication Number Publication Date
IL84275A true IL84275A (en) 1993-04-04

Family

ID=25464076

Family Applications (1)

Application Number Title Priority Date Filing Date
IL84275A IL84275A (en) 1986-11-21 1987-10-25 Pharmaceutical composition comprising erythropoietin for treatment of iron overload disorders

Country Status (16)

Country Link
US (1) US5013718A (de)
EP (1) EP0269394B1 (de)
JP (1) JPH0692316B2 (de)
KR (1) KR950009100B1 (de)
AT (1) ATE68352T1 (de)
AU (1) AU602028B2 (de)
CA (1) CA1322165C (de)
DE (1) DE3773852D1 (de)
DK (1) DK167650B1 (de)
ES (1) ES2039252T3 (de)
GR (1) GR3003254T3 (de)
IE (1) IE60865B1 (de)
IL (1) IL84275A (de)
NZ (1) NZ222432A (de)
PT (1) PT86187B (de)
WO (1) WO1988003808A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO881507D0 (no) * 1987-04-10 1988-04-07 Ortho Pharma Corp Fremgangsmaate for forhoeyning av hematokritnivaaet til et normalt pattedyr.
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
ATE251912T1 (de) 1994-11-03 2003-11-15 Roche Diagnostics Gmbh Verwendung des erythropoietins zur behandlung von rheumatoider arthritis
CA2216443A1 (en) 1995-03-31 1996-10-03 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
TW586933B (en) * 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
EP0965349A1 (de) * 1998-06-18 1999-12-22 Roche Diagnostics GmbH Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
WO2001035095A2 (en) * 1999-11-12 2001-05-17 Rothenberg Barry E Diagnostic test for hemochromatosis
US7160855B2 (en) * 2002-03-14 2007-01-09 Children's Hospital & Research Center At Oakland Enhancement of iron chelation therapy
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
US10694962B2 (en) 2011-06-13 2020-06-30 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
WO2012174157A1 (en) * 2011-06-13 2012-12-20 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
FR3037592B1 (fr) 2015-06-18 2017-06-09 Michelin & Cie Pneumatique pourvu d'une bande de roulement comprenant un elastomere dienique et un systeme d'elastomeres thermoplastiques
CA3193654A1 (en) 2020-10-02 2022-04-07 Jasbir S. Seehra Methods of using activin receptor type ii variants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification

Also Published As

Publication number Publication date
DK407488D0 (da) 1988-07-21
NZ222432A (en) 1990-07-26
DE3773852D1 (de) 1991-11-21
KR950009100B1 (ko) 1995-08-14
KR890700032A (ko) 1989-03-02
PT86187B (pt) 1990-11-07
EP0269394A3 (en) 1988-09-14
ES2039252T3 (es) 1993-09-16
JPH0692316B2 (ja) 1994-11-16
IE60865B1 (en) 1994-08-24
AU8179487A (en) 1988-06-16
PT86187A (en) 1987-12-01
GR3003254T3 (en) 1993-02-17
DK167650B1 (da) 1993-12-06
ATE68352T1 (de) 1991-11-15
DK407488A (da) 1988-07-21
EP0269394B1 (de) 1991-10-16
CA1322165C (en) 1993-09-14
JPS63159322A (ja) 1988-07-02
EP0269394A2 (de) 1988-06-01
US5013718A (en) 1991-05-07
WO1988003808A1 (en) 1988-06-02
IE873113L (en) 1988-05-21
AU602028B2 (en) 1990-09-27

Similar Documents

Publication Publication Date Title
IL84275A (en) Pharmaceutical composition comprising erythropoietin for treatment of iron overload disorders
PT85285A (en) Process for producing il-6 and of pharmaceutical compositions containing the same
MY101209A (en) Production of m-csf.
RU93052390A (ru) Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении
AU598020B2 (en) Cosmetic composition
PT82619A (en) Process for the preparation of a therapeutic composition for the local treatment of dandruff seborrrheic dermatitis and psoriasis
PT87197A (pt) Processo para preparacao de agentes terapeuticos eritropoietina
AU1553388A (en) Treatment of diabetes
OA07002A (fr) Dérivé de la pyrrolidine, sa préparation et ses utilisations thérapeutiques pour le traitement de l'insuffisance cérébrale.
EP0306191A3 (de) 2,3-Dihydroergoline zur Steigerung serotonerger Funktionen
OA09455A (fr) Nouveaux polyols furanniques, utilisation de ceux-ci comme polyols dans la formation de polyuréthannes, polyuréthannes ainsi obtenus et leur procédé de préparation.
IE820151L (en) Treating shock using meptazinol
PT80214A (en) Process for the preparation of a pharmaceutical composition containing 9alpha,11beta-dichloro 16alpha-methyl 21-oxycarbonyldicyclohexyl-methyloxi-pregne-1,4-diene 3,20-dione as active agent and an inert product as excipient appropriate to permit r said composition to be used in the rectum or colon
EP0202778A3 (de) Verwendung von (S)-2-Amino-5-hydroxy-4-oxopentansäure zur Herstellung eines Arzneimittels zur Behandlung von System-Mykosis
JPS6442470A (en) Guanidinecarboxylic acid esters, manufacture and medicinal composition
FR2616430B1 (fr) Nouveaux diesters de l'acide azelaique, leur procede de preparation, les compositions topiques les contenant et leur utilisation dans le traitement de l'acne
ES428172A1 (es) Un procedimiento para preparar acido 5-pivaloiloxi-5-(1-fe-niletil)-barbiturico.
UA7216A1 (uk) Спосіб одержання похідних 12-аміно-пірідазіно[4', 5':3,4]-пірроло[2,1-а] ізохіноліна або їх фізіологічно переносимих кислотно-аддітивних солей
IT8421682U1 (it) Pressa per l'applicazione di puntali al tomaio nella fabbricazione di calzature.
MA19564A1 (fr) Derives de la pyrrolidine, sa preparation et ses utilisations therapeutiques pour le traitement de l'insuffisance cerebrale
AU7931487A (en) Therapeutic treatment of abnormal cell growth with follicle regulatory protein
BG52067B2 (en) Antihypoxic and brain-protection antidote composition

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired